Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash-to-Debt 0.01
AMEX:NAVB's Cash-to-Debt is ranked lower than
99% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. AMEX:NAVB: 0.01 )
Ranked among companies with meaningful Cash-to-Debt only.
AMEX:NAVB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.51 Max: No Debt
Current: 0.01
Equity-to-Asset -5.74
AMEX:NAVB's Equity-to-Asset is ranked lower than
100% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AMEX:NAVB: -5.74 )
Ranked among companies with meaningful Equity-to-Asset only.
AMEX:NAVB' s Equity-to-Asset Range Over the Past 10 Years
Min: -7.42  Med: 0.36 Max: 0.91
Current: -5.74
-7.42
0.91
Piotroski F-Score: 5
Altman Z-Score: -52.02
Beneish M-Score: -7.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -10.44
AMEX:NAVB's Operating Margin % is ranked higher than
66% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. AMEX:NAVB: -10.44 )
Ranked among companies with meaningful Operating Margin % only.
AMEX:NAVB' s Operating Margin % Range Over the Past 10 Years
Min: -35429.11  Med: -290.2 Max: -10.44
Current: -10.44
-35429.11
-10.44
Net Margin % -56.47
AMEX:NAVB's Net Margin % is ranked higher than
54% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. AMEX:NAVB: -56.47 )
Ranked among companies with meaningful Net Margin % only.
AMEX:NAVB' s Net Margin % Range Over the Past 10 Years
Min: -36907.59  Med: -312.08 Max: 938.63
Current: -56.47
-36907.59
938.63
ROA % -100.12
AMEX:NAVB's ROA % is ranked lower than
85% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. AMEX:NAVB: -100.12 )
Ranked among companies with meaningful ROA % only.
AMEX:NAVB' s ROA % Range Over the Past 10 Years
Min: -502.64  Med: -136.06 Max: 26.69
Current: -100.12
-502.64
26.69
ROC (Joel Greenblatt) % -136.30
AMEX:NAVB's ROC (Joel Greenblatt) % is ranked higher than
62% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. AMEX:NAVB: -136.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMEX:NAVB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8007.05  Med: -1014.19 Max: -117.97
Current: -136.3
-8007.05
-117.97
3-Year Revenue Growth Rate 344.80
AMEX:NAVB's 3-Year Revenue Growth Rate is ranked higher than
99% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. AMEX:NAVB: 344.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMEX:NAVB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -80.2  Med: 2.5 Max: 344.8
Current: 344.8
-80.2
344.8
3-Year EBITDA Growth Rate -24.90
AMEX:NAVB's 3-Year EBITDA Growth Rate is ranked lower than
77% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. AMEX:NAVB: -24.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AMEX:NAVB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -46.5  Med: -12.9 Max: 141.3
Current: -24.9
-46.5
141.3
3-Year EPS without NRI Growth Rate -13.10
AMEX:NAVB's 3-Year EPS without NRI Growth Rate is ranked lower than
61% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. AMEX:NAVB: -13.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AMEX:NAVB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -5.3 Max: 112.9
Current: -13.1
0
112.9
GuruFocus has detected 3 Warning Signs with Navidea Biopharmaceuticals Inc $AMEX:NAVB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMEX:NAVB's 10-Y Financials

Financials (Next Earnings Date: 2017-03-23)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016
Q2 2016
Q3 2016
Q4 2016
» Details

Insider Trades

Latest Guru Trades with NAVB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325413    SIC: 2835
Compare:AMEX:PIP, NAS:BLRX, NAS:IPCI, NAS:AGLE, NAS:KALV, NAS:GTXI, OTCPK:IMMG, NAS:PULM, NAS:CBAY, NAS:BUR, NAS:BCLI, OTCPK:CWBR, NAS:CAPR, OTCPK:TBQBF, OTCPK:CNNRF, NAS:SBPH, NAS:ALDX, NAS:TTNP, NAS:ADMA, NAS:AXSM » details
Traded in other countries:NO1.Germany,
Navidea Biopharmaceuticals Inc is a precision medicine company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents.

Navidea Biopharmaceuticals Inc was incorporated in Ohio in 1983 and reincorporated in Delaware in 1988. It is a biopharmaceutical company engaged in the development and commercialization of precision diagnostics and radiopharmaceutical agent. Its products include Lymphoseek Injection is a novel, receptor-targeted, small-molecule radiopharmaceutical used in lymphatic mapping procedures that are performed to help evaluate patients with breast cancer and melanoma. Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on macrophages. This flexible and versatile platform acts as an engine for the design of purpose-built molecules offering the potential to be utilized across a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography, intra-operative and/or optical-fluorescence detection in a variety of disease states. NAV4694 is a Fluorine-18 radiolabeled PET imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. NAV5001 is an Iodine-123 radiolabeled SPECT imaging agent being developed as an aid in the diagnosis of Parkinson's disease and other movement disorders, with potential use as a diagnostic aid in dementia. NAV1800 is a radiolabeled monoclonal antibody being developed as a diagnostic aid for use during surgery to help surgeons locate occult or metastatic cancer, with a focus on colorectal cancer. It faces competition from medical product and biotechnology companies, as well as from universities and other non-profit research organizations in the field of cancer diagnostics and treatment. As a developer, manufacturer and marketer of medical products, the Company is subject to regulation by, among other governmental entities, FDA and the corresponding state, local and foreign regulatory bodies in jurisdictions in which its products are sold.

Ratios

vs
industry
vs
history
PS Ratio 3.18
NAVB's PS Ratio is ranked higher than
82% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. NAVB: 3.18 )
Ranked among companies with meaningful PS Ratio only.
NAVB' s PS Ratio Range Over the Past 10 Years
Min: 1.86  Med: 15.3 Max: 3570
Current: 3.18
1.86
3570
Current Ratio 0.15
NAVB's Current Ratio is ranked lower than
97% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. NAVB: 0.15 )
Ranked among companies with meaningful Current Ratio only.
NAVB' s Current Ratio Range Over the Past 10 Years
Min: 0.11  Med: 2.64 Max: 12.28
Current: 0.15
0.11
12.28
Quick Ratio 0.14
NAVB's Quick Ratio is ranked lower than
97% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. NAVB: 0.14 )
Ranked among companies with meaningful Quick Ratio only.
NAVB' s Quick Ratio Range Over the Past 10 Years
Min: 0.1  Med: 2.24 Max: 12.11
Current: 0.14
0.1
12.11
Days Inventory 115.39
NAVB's Days Inventory is ranked higher than
54% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. NAVB: 115.39 )
Ranked among companies with meaningful Days Inventory only.
NAVB' s Days Inventory Range Over the Past 10 Years
Min: 98.26  Med: 137 Max: 1386.56
Current: 115.39
98.26
1386.56
Days Sales Outstanding 55.35
NAVB's Days Sales Outstanding is ranked higher than
55% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. NAVB: 55.35 )
Ranked among companies with meaningful Days Sales Outstanding only.
NAVB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 9.77  Med: 76.68 Max: 1211.54
Current: 55.35
9.77
1211.54
Days Payable 705.36
NAVB's Days Payable is ranked higher than
97% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. NAVB: 705.36 )
Ranked among companies with meaningful Days Payable only.
NAVB' s Days Payable Range Over the Past 10 Years
Min: 88.95  Med: 93.14 Max: 2654.74
Current: 705.36
88.95
2654.74

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.30
NAVB's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. NAVB: -11.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NAVB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.2  Med: -11.3 Max: -0.7
Current: -11.3
-25.2
-0.7

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.21
NAVB's Price-to-Median-PS-Value is ranked higher than
94% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. NAVB: 0.21 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NAVB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 0.37 Max: 141.5
Current: 0.21
0.05
141.5
Earnings Yield (Greenblatt) % -1.58
NAVB's Earnings Yield (Greenblatt) % is ranked higher than
71% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. NAVB: -1.58 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NAVB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -14.2  Med: 0 Max: 0
Current: -1.58
-14.2
0

More Statistics

Revenue (TTM) (Mil) $22.91
EPS (TTM) $ -0.12
Beta-0.71
Short Percentage of Float8.68%
52-Week Range $0.26 - 1.51
Shares Outstanding (Mil)161.19
» More Articles for NAVB

Headlines

Articles On GuruFocus.com
Navidea Biopharmaceuticals Reports 4 Insider Trades Mar 18 2013 

More From Other Websites
Cardinal Health helps Navidea settle lender's payoff – for now Feb 24 2017
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Feb 23 2017
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Feb 16 2017
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 10 2017
Navidea to Hold Conference Call to Provide Investor Update on Status of Ongoing Corporate Events Jan 27 2017
Navidea to Present at Upcoming Investor Conference Jan 06 2017
Navidea to Present at Upcoming Investor Conference Jan 06 2017
ETFs with exposure to Navidea Biopharmaceuticals, Inc. : December 29, 2016 Dec 29 2016
ETFs with exposure to Navidea Biopharmaceuticals, Inc. : December 13, 2016 Dec 13 2016
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Nov 30 2016
Edited Transcript of NAVB earnings conference call or presentation 3-Nov-16 12:30pm GMT Nov 28 2016
ETFs with exposure to Navidea Biopharmaceuticals, Inc. : November 28, 2016 Nov 28 2016
Navidea Signs Asset Purchase Agreement with Cardinal Health Nov 23 2016
Navidea Signs Asset Purchase Agreement with Cardinal Health Nov 23 2016
NAVIDEA BIOPHARMACEUTICALS, INC. Financials Nov 17 2016
Navidea Biopharmace21860helestones Nov 14 2016
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 09 2016
ETF’s with exposure to Navidea Biopharmaceuticals, Inc. : November 8, 2016 Nov 08 2016
Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7,... Nov 07 2016
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)